More stories

  • in

    Ford reports 7.7% increase in third-quarter sales

    Ford Motor’s third-quarter U.S. new vehicle sales increased 7.7% compared to a year earlier, driven by increased sales of trucks across its lineup.
    An ongoing strike by the United Auto Workers union against the Detroit automakers, including Ford, was not expected to directly impact sales during the quarter.

    United Auto Workers members strike at the Ford Michigan Assembly Plant on September 15, 2023 in Wayne, Michigan. 
    Bill Pugliano | Getty Images

    DETROIT – Ford Motor’s third-quarter U.S. new vehicle sales increased 7.7% compared to a year earlier, driven by increased sales of traditional pickup trucks across its lineup.
    The Detroit automaker on Wednesday reported a 15.3% increase in truck sales compared to a 5.1% decline in cars and sales of SUVS that were essentially flat.

    An ongoing strike by the United Auto Workers union against the Detroit automakers, including Ford, was not expected to directly impact sales during the quarter.
    This is a developing story. Please check back for additional updates. More

  • in

    Stocks making the biggest moves premarket: Cal-Maine Foods, Intel, Apple & more

    Signage outside Intel headquarters in Santa Clara, California, Jan. 30, 2023.
    David Paul Morris | Bloomberg | Getty Images

    Check out the companies making headlines before the bell.
    Intel — Shares popped 2.5% after the chipmaker announced it would be operating its programmable chip unit as a standalone business complete. Intel plans to conduct an initial public offering for the unit within the next two to three years.

    Fluor —  Shares climbed 2.4% following an upgrade to buy at UBS. The firm is bullish on the stock thanks to progress on legacy projects and said Fluor is on the brink of a company turning point. 
    Apple — The iPhone maker shed 0.9% after KeyBanc cut its rating on Apple to sector weight from overweight late Tuesday, citing shares’ high valuation and an expectation for soft growth in the United States.
    Sunrun, Sunnova Energy International — Shares of Sunrun and Sunnova dropped 3% and 2.8%, respectively, after Truist Securities downgraded the solar panel installers to hold from buy on Wednesday. The firm said higher-for-longer interest rates could hit solar energy stocks.
    Moderna — The pharma stock rose slightly after Moderna announced positive interim results from the Phase 1/2 trial of mRNA-1083, an investigational combination vaccine against influenza and Covid. Moderna said in a press release it plans to begin a Phase 3 trial of the combination vaccine in 2023, working to accomplish potential regulatory approval in 2025.
    Oddity — The Israel-based beauty stock, which owns direct-to-consumer brands Il Makiage and SpoiledChild, added 3.2% after Bank of America upgraded it to buy from neutral. The bank said it expects sustainable annual sales growth and margin expansion.

    Novartis — Shares lost 3.7% after the Swiss drugmaker completed the spinoff of its generics and biosimilars business Sandoz, which dipped on its market debut on the SIX Swiss Exchange.
    Cal-Maine Foods — The stock plunged 11.6% after the company came out with disappointing sales figures due to lower prices. The egg producer reported fiscal first-quarter earnings of two cents per share, while analysts polled by StreetAccount had called for earnings of 33 cents per share. Revenue was also lackluster.
    — CNBC’s Brian Evans and Lisa Han contributed reporting. More

  • in

    Moderna combination Covid, flu vaccine moves to final stage trial after positive data

    Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial after showing positive results in an earlier study.
    The biotech company is hoping its shot, mRNA-1083, can win approval from regulators in 2025. 
    Moderna and other vaccine makers like Pfizer believe combination shots will simplify what people can do to protect themselves against respiratory viruses that typically surge at the same time of the year.

    Artur Widak | Nurphoto | Getty Images

    Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial in adults ages 50 and above this year after showing positive results in an early to mid-stage study.
    The biotech company hopes its shot, mRNA-1083, can win approval from regulators in 2025. 

    Moderna and other vaccine makers like Pfizer believe combination vaccines will simplify what people can do to protect themselves against respiratory viruses that typically surge around the same time of the year.
    “Combination vaccines offer an important opportunity to improve consumer and provider experience, increase compliance with public health recommendations, and deliver value for healthcare systems,” Moderna CEO Stéphane Bancel said in a statement. 
    “We are excited to move combination respiratory vaccines into Phase 3 development and look forward to partnering with public health officials to address the significant seasonal threat posed to people by these viruses,” he added.
    The mRNA-1083 shot generated an immune response similar to or greater than two currently available flu vaccines from GlaxoSmithKline in the early to mid-stage clinical trial. 
    Moderna’s combination shot also produced an immune response similar to its bivalent Covid vaccine, which targets the omicron variants BA.4 and BA.5 and the original strain of the virus. 

    The trial evaluated the combination shot in two different age groups: people 50 to 64 years of age and participants 65 to 79. 
    The safety data of mRNA-1083 was similar to that of the stand-alone Covid shot, according to Moderna. No new safety concerns were identified with the combination vaccine. 
    Moderna is also developing a combination shot targeting the flu and RSV, and another vaccine targeting all three respiratory viruses: Covid, flu and RSV. 
    Meanwhile, Pfizer and BioNTech also are developing a vaccine that targets both Covid and the flu. The companies started a phase one trial for the shot in November and said they expect to launch it in 2024 or later. More

  • in

    Mortgage demand drops to the lowest level since 1996, as interest rates head toward 8%

    The average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances ($726,200 or less) increased to 7.53% from 7.41%.
    Applications to refinance a home loan dropped 7% for the week and were 11% lower than the same week one year ago.
    Applications for a mortgage to purchase a home fell 6% for the week and were 22% lower than the same week one year ago.

    A house is for sale in Arlington, Virginia, July 13, 2023.
    Saul Loeb | AFP | Getty Images

    Mortgage rates just continue to climb higher, taking a particularly big leap last week. As a result, total mortgage demand fell 6% compared with the previous week, according to the Mortgage Bankers Association’s seasonally adjusted index.
    The average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances ($726,200 or less) increased to 7.53% from 7.41%, with points rising to 0.80 from 0.71 (including the origination fee) for loans with a 20% down payment. That rate was 6.75% the same week one year ago.

    “Mortgage rates continued to move higher last week as markets digested the recent upswing in Treasury yields,” said Joel Kan, MBA’s vice president and deputy chief economist. “As a result, mortgage applications ground to a halt, dropping to the lowest level since 1996.”
    Applications to refinance a home loan dropped 7% for the week and were 11% lower than the same week one year ago. Refinances now make up less than one-third of all mortgage applications. Just two years ago, when rates were setting multiple record lows, refinance demand made up roughly three-quarters of all mortgage applications.
    Applications for a mortgage to purchase a home fell 6% for the week and were 22% lower than the same week one year ago.
    “The purchase market slowed to the lowest level of activity since 1995, as the rapid rise in rates pushed an increasing number of potential homebuyers out of the market,” said Kan, who also noted that adjustable-rate mortgage (ARM) applications increased. The ARMs made up 8% of purchase applications, up from 6.7% about a month ago, when interest rates were slightly lower. ARM’s offer lower rates but are fixed for a shorter term, usually five or 10 years.
    A separate, daily survey on mortgage rates from Mortgage News Daily showed the average rate on the 30-year fixed rising even higher this week, hitting 7.72% on Tuesday. Investors are responding to better-than-expected economic data, which could push the Federal Reserve to be more aggressive in its higher interest rate policy. More

  • in

    Bond yields could race through 5% in next couple of weeks, market forecaster Jim Bianco warns

    Fast Money Podcast
    Full Episodes

    Wall Street forecaster Jim Bianco expects Treasury yields to go a lot higher — and possibly overshoot through 5% in the next couple of weeks.
    “I don’t think we’re near the end of this move in the bond market,” the Bianco Research president told CNBC’s “Fast Money” on Tuesday.

    If the Federal Reserve hints about ending interest rate hikes while investors still sense inflation, Bianco warns they won’t buy bonds.
    “That’s what I think has been killing the bond market,” he said. “The more the Fed talks about being done, waiting [and] assessing all the rate hikes they’ve done — the more that they’re making it worse.”
    Yields on the 5-year and 10-year Treasury notes, as well as the 30-year Treasury bond, hit their highest levels since 2007. The 10-year Treasury yield reached 4.8% on Tuesday. Bianco sees 4.5% as fair value.
    “We’re just a little bit above fair value right now. I think what you see in the bond market is a capitulation,” noted Bianco. “Most of the year bond investors [and] bond managers have been long. They’ve been trying to argue why we’re going to have a recession. Why there’s going to be a rally. And, they’ve been getting their brains beat in, and they can’t take it anymore.”
    The volatility in the bond market is extending to stocks. The Dow Jones Industrial Average saw its worst daily performance since March and is now negative for the year. The S&P 500 and the Nasdaq Composite also closed the day more than 1% lower.

    The latest jitters over surging yields come a day after CNBC on-air editor Rick Santelli delivered a warning to investors on “Fast Money.”
    “We have a lot of potential room to run to the upside,” Santelli said on Monday. “If somebody asked me and held a gun to my head and said ‘listen, [in] the worst-case scenario, where are Treasury rates going to go? 10-year?’ I’d say in the next seven years, you should be able to see 13.5%, 14%.”
    Bianco considers yields that high an extreme situation. “13%? That would take something bad to happen — a lot worse than I anticipate,” he said.
    Disclaimer More

  • in

    Bill Gross says the surging 10-year Treasury yield could test 5% in the short term

    Bill Gross, Portfolio Manager, Janus Capital Group
    Lucy Nicholson | Reuters

    Widely followed investor Bill Gross believes Treasury yields have the potential to shoot even higher in the short run.
    “I think we’re gonna go to five [percent],” Gross said on CNBC’s “Last Call” on Tuesday, referring to the 10-year Treasury yield. “The market certainly is oversold at the moment in anticipation of Treasury supplies, in anticipation of higher for longer in terms of the Fed.”

    The stock market suffered a severe sell-off Tuesday as surging bond yields rattled Wall Street. The S&P 500 dropped 1.4%, touching its lowest level since June during the day as the 10-year Treasury yield reached its highest point in 16 years.
    The benchmark yield has surged in the past month to touch 4.8% as the Federal Reserve pledged to keep interest rates at a higher level for longer. The 30-year Treasury yield hit 4.9% Tuesday, also the highest since 2007.

    Stock chart icon

    10-year Treasury yield

    “I think maybe 5% caps it for the near term. It depends, of course, on inflation, depends on economic growth,” the former chief investment officer and co-founder of Pimco said.
    Billionaire investor Ray Dalio also said Tuesday that the surging 10-year rate could test 5% as he sees hotter inflation for longer.
    Gross, once known as the bond king, believes that the Fed’s aggressive rate hikes undertaken since March 2022 have had a significant effect on the yield curve. The central bank has taken interest rates to the highest level since early 2001.

    Gross said investors are now grappling with the negative impact that comes from a deepening Treasury deficit.
    “What we’re seeing is a recognition of the Treasury deficit that is $2 trillion-plus, and that’s affecting the long end, as is, I think, in the last few days, the selling of ETFs, which basically own long bonds as opposed to short bonds,” Gross said. More

  • in

    The job market is strong, economists say — but workers don’t think so

    The job market looks a lot like one that preceded the Covid-19 pandemic: one characterized by low unemployment and good job opportunities, economists said.
    Workers’ confidence has deteriorated, though.
    That’s partly because of financial stress amid higher interest rates and inflation, economists said.

    Hinterhaus Productions | The Image Bank | Getty Images

    The job market remains strong despite gradual cooling from pandemic-era highs, according to labor economists — but workers don’t seem to share that outlook.
    Employee confidence fell last month to its lowest level since 2016, according to Glassdoor data. About 46% of workers reported a positive six-month outlook for their employers, down from 54% from a year ago.

    Meanwhile, the ZipRecruiter Job Seeker Confidence Index was down six points in the second quarter to its lowest point since the beginning of 2022.
    More from Personal Finance:Supreme Court case may gut the CFPBStudent loan bills resume for 40 million AmericansHere are the top 10 highest-paying college majors
    The juxtaposition of a resilient labor market but deteriorating sentiment is likely due to financial stress among workers and the fact that the recent baseline was a scorching-hot job market in 2021 and 2022, economists said.
    “Overall, workers still have more leverage and more job security than before the pandemic,” said Julia Pollak, chief economist at ZipRecruiter.
    “I think job seekers comparing this environment to 2021 and 2022 do feel worse off,” she added. “It’s taking more effort to find a job, and jobseekers are searching under greater financial strain now.”

    The job market is stable but not ‘gangbusters’

    Several metrics — including job openings, quits, layoffs and the unemployment rate — suggest the labor market is healthy, economists said.
    Daniel Zhao, lead economist at Glassdoor, said it is “softer but steady.”
    “If you look at these indicators in aggregate, they point to a labor market that isn’t necessarily going gangbusters, but in a fairly stable state,” Zhao said.
    Broadly, the indicators are largely in line or even stronger than pre-pandemic, a time when unemployment was low, people were joining the labor force and gender and racial employment gaps were narrowing, Pollak said.

    I think a lot of folks are comparing the labor market today to a year or two ago when things were hot. But of course, there were also problems with the economy of 2021 and 2022.

    Daniel Zhao
    lead economist at Glassdoor

    “That’s a very good thing,” she said.
    The quits rate — a barometer of workers’ willingness or ability to leave a job — was 2.3% in August, the same as February 2020, the U.S. Department of Labor reported Tuesday.
    It was unchanged from July, though down from a 3% peak in April 2022 when a record number of workers were quitting, in what became known as the great resignation.
    Likewise, the hiring rate is slightly below but roughly similar to its level in February 2020.
    Layoffs are still 15% lower than before the Covid-19 pandemic and job openings — a gauge of employers’ demand for workers — are 37% higher, according to Labor Department data.

    The problems with the 2021, 2022 job markets

    In fact, job openings rose significantly, by 690,000, to 9.6 million in August, the Labor Department reported Tuesday.
    However, there are reasons to think that increase is anomalous, economists said. For one, the data series is generally volatile, subject to big ups and downs from month to month. The broader trend is clear: Job openings, along with quits and hires, have cooled from their pandemic-era peaks, economists said.
    “I think a lot of folks are comparing the labor market today to a year or two ago when things were hot,” Zhao said. “But of course, there were also problems with the economy of 2021 and 2022.”

    Among the problems: Inflation touched its highest level since 1981, eroding the big raises workers had been getting due to lost purchasing power. Also, certain sectors such as technology hired overzealously, Zhao said, leading big tech firms to lay off tens of thousands of people.
    A labor market that runs too hot is unsustainable, as job turnover and wage growth get so high that they feed into inflation, Zhao said. It’s unclear the extent to which this may have occurred in the recent inflationary bout.
    “The labor market that we’re getting today is in a healthier spot, even though for many workers, it isn’t quite as easy to find a job or get a raise,” Zhao said.
    Of course, it’s unclear if — and the extent to which — the labor market will continue cooling, economists said. In addition to higher interest rates, there are economic headwinds such as continued strikes by auto workers, high oil prices and another government shutdown threat looming in November, Zhao said. More

  • in

    Novavax updated Covid vaccine wins FDA, CDC backing, paving way to reach Americans within days

    Novavax’s updated Covid vaccine won the backing of the FDA and CDC.
    That puts the shot, which targets XBB.1.5, on track to roll out weeks after new jabs from Pfizer and Moderna reached Americans.
    Health officials see Novavax’s protein-based vaccine as a valuable alternative for people who don’t want to take messenger RNA shots from Pfizer and Moderna.

    A vial labelled “Novavax V COVID-19 Vaccine” is seen in this illustration taken January 16, 2022. 
    Dado Ruvic | Reuters

    Novavax’s updated Covid vaccine won the backing of U.S. regulators on Tuesday, putting the shot on track to roll out weeks after new jabs from Pfizer and Moderna reached Americans.
    The Food and Drug Administration authorized Novavax’s single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up.

    The Centers for Disease Control and Prevention is now including Novavax’s shot in the same recommendation it issued last month for updated vaccines from Pfizer and Moderna. That recommendation says all Americans ages six months and older can receive an updated Covid jab.
    Novavax said in a statement that doses of the shot will likely be available within the next few days.
    “Novavax’s authorization today means people will now have the choice of a protein-based non-MRNA option to help protect themselves against Covid-19, which is now the fourth leading cause of death in the U.S.,” said Novavax CEO John Jacobs in the statement. “In the coming days, individuals in the U.S. can go to major pharmacies, physicians’ offices, clinics and various government entities to receive an updated Novavax vaccine.” 
    Public health officials see Novavax’s vaccine as a valuable alternative for people who don’t want to take messenger RNA shots from Pfizer and Moderna, which teach cells how to make proteins that trigger an immune response against Covid. Novavax’s shot fends off the virus with protein-based technology, a decades-old method used in routine vaccinations against hepatitis B and shingles.
    Around 2 million Americans have received the updated Covid vaccines from Pfizer and Moderna so far, the Biden administration said last week, even as patients eager to get their dose have been met with unexpected insurance delays and availability issues.

    Regardless, all three shots are expected to help the U.S. combat the spread of Covid this fall and winter, when the virus usually spreads at higher levels. 
    The nation is already seeing a surge in cases and hospitalizations. While levels remain far below previous Covid waves in the U.S., it’s still the first notable uptick since last winter and has even prompted the return of mask mandates for a handful of businesses and schools. 
    The rise is driven by newer strains of the virus that are gaining ground nationwide as XBB.1.5 gradually declines. That includes EG.5, or Eris, an omicron strain that accounted for 29.4% of all cases as of Saturday, according to the CDC. 
    A Novavax spokesperson said last month its new Covid vaccine generated a “broad immune response” against Eris and another fast-spreading strain called XBB.1.16.6 – both of which are descendants of omicron.  
    But it’s unclear whether the company’s new vaccine will protect against BA.2.86, a highly mutated omicron strain that health officials are watching closely despite its small number of cases. Novavax last month said it was still testing its vaccine against BA.2.86.
    The rollout of Novavax’s new shot comes months after the end of the U.S. Covid public health emergency. 
    The end of that declaration means all three manufacturers will sell their updated shots directly to health-care providers and vie for commercial market share.  Previously, the government purchased vaccines directly from manufacturers at a discount to distribute to all Americans for free. 
    During the advisory meeting last month, Novavax said the list price of its vaccine is $130 per dose.
    Federal and corporate programs are aiming to fill the gap for uninsured Americans. That includes the Biden administration’s Bridge Access Program, which will provide Covid vaccines at no cost to underinsured and uninsured people. 
    It’s unclear how many Americans will actually roll up their sleeves and take the new vaccines from Novavax, Pfizer and Moderna.
    But roughly 42% of Americans surveyed by the CDC in August said they “definitely will” or “probably will” get a Covid shot this fall, Dr. Megan Wallace, a CDC epidemiologist, said during the advisory meeting. More